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Introduction
Globally, approximately 530,000 new cases of cervical 
cancer (CC) occur each year, with 85% of these cases 
occurring in low- and middle-income countries (LMICs) 
(Globocan, 2012). The human papillomavirus vaccines 
(HPV) currently available include Cervarix® (2vHPV, 
GlaxoSmithKline), Gardasil® (4vHPV, Merck and Co., 
Inc.) and the recently licensed Gardasil® 9 (9vHPV, 
Merck and Co., Inc.) (Table 1), have huge potential in 
preventing the majority of CC and other HPV-associated 
diseases, based on the high vaccine efficacy against CC 
precursors observed in clinical and post-marketing studies 
(Future II study group, 2007; Paavonen et al., 2009; Joura 
et al., 2015). A systematic review of the 4vHPV 10 years 
post-licensure, demonstrated dramatic reductions in 
vaccine and vaccine–related HPV type infection and short 
incubation HPV diseases (i.e. genital warts), as well as 
low- and high-grade cervical dysplasia. In countries with 
high vaccination coverage. In addition, herd protection 
has also been found in these populations (Garland et al., 
2016). The 9vHPV is approved for use in USA, Canada 
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and Europe, and while both 4vHPV and 2vHPV are in use 
in most high-income countries around the world, their use 
in LMICs is mainly limited to the private sector due to 
their high cost, low demand and logistical challenges in 
delivering multiple doses of the vaccine to a school-age 
population. 
Many countries in Asia have not introduced HPV 
vaccine into their national immunization program.
There are also large disparities in CC incidence between 
countries of Asia, with the highest rates in LMICs due to 
poor diagnosis and treatment, as well as the lack of access 
to HPV vaccines due to their high costs and logistical 
difficulties in vaccine implementation. Furthermore, 
many LMICs do not have accurate CC burden data to 
justify the cost-effectiveness and use of HPV vaccines. 
Social and cultural issues associated with HPV infection 
have also impeded the use of these important vaccines. It 
is therefore critical that justification for the use of HPV 
vaccines be based on accurate and reliable CC burden and 
cost-effectiveness data, especially  for LMICs in Asia. This 
article highlights the significant burden of cervical cancer 
in LMICs and the potential impact of HPV vaccines in CC 
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prevention. Moreover, the contribution of philanthropic 
organisations as well as strategies to overcome some of 
the recognised barriers to HPV vaccine introduction are 
also discussed. 
Burden of cervical cancer in Asia
Cervical cancer remains the second highest cause of 
morbidity and mortality among women in Asia (Bruni 
et al., 2015). As in other regions, HPV16 and 18 are the 
most common types in Asia, and the percentage of CC 
deaths attributed to these two types ranges from 48%-88% 
depending on the country (Bruni L et al., 2015), indicating 
that many of these deaths are vaccine preventable. 
Actual CC data based on available cancer 
registries in Asia are very limited and are mainly from 
middle- to high-income countries (summarised in Table 2). 
Furthermore, a huge disparity in the CC incidence exists 
between these countries. For LMICs in Asia, data on CC 
rates are largely derived from Globocan and are mainly 
estimates based on modelled data from neighbouring 
countries as cervical cancer registries are limited and 
cases are under reported (Globocan, 2012). Accurate 
disease burden data are important to justify the need for 
HPV vaccination, as well as ultimately measuring vaccine 
effectiveness. For example, the burden of cervical cancer 
in Fiji was not known until epidemiological data was 
collected from both the national cancer registries and 
laboratory records. Fiji has one of the highest CC rates in 
Manufacturer Merck™ GlaxoSmithKline™ Merck™
(Gardasil®, 4vHPV) (Cervarix®, 2vHPV) (Gardasil® 9, 9vHPV)
L1 VLP types 6, 11, 16 and 18 16 and 18
6, 11, 16, 18, 
31, 33, 45, 52, and 58
Dose 20/40/40/20 µg 20/20 µg
30/40/60/40/
20/20/20/20/20 
Producer cells
Saccharomyces cerevisiae 
(baker’s yeast) expressing L1
Trichoplusia ni (Hi 5) insect cell line 
infected with L1 recombinant baculovirus 
Saccharomyces cerevisiae 
(baker’s yeast) expressing L1
Adjuvant
225 µg aluminium 
hydroxyphosphate sulfate 
500 µg aluminium hydroxide, 50 µg 
3-O-deacylated-4’-monophosphoryl lipid A
500 µg aluminium 
hydroxyphosphate sulfate
*Vaccination schedule 0, 2 and 6 months 0, 1 and 6 months 0, 2 and 6 months
Table 1. Characteristics of HPV VLP Vaccines
HPV, Human papillomavirus; VLP, Virus-like particles; * WHO recommends two-dose schedule for girls <15 years old, provided the second dose 
is given at least six months apart 
Source of data: (Forman D and E, 2014); *suspended in 2013 (<1% coverage); ASR, Age-standardised rate; No., number; ^ CC incidence rates based 
on cancer registry from multiple cities within the country 
Country based on WHO 
regional offices
No. of CC 
cases 
Frequency 
of CC (%)
Crude rate/ 
100,000
ASR/ 
100,000
HPV vaccination 
program
Estimated coverage of 
cervical cancer screening (%) 
     Eastern Mediterranean
     Bahrain 44 3.7 3.9 5.7 No 43.1
     Kuwait 161 4.1 3 4.6 No 22.3
     Islamic Republic of Iran, 
(Golestan Province)
91 3.8 3.7 5.4 No 49.4
     Israel 918 1.6 5.5 5 National 32
     Qatar 17 3.6 3.4 5.3 No 39.4
     Saudi Arabia 103 1.9 1.1 2 No No data
Western Pacific 
     ^China 40-2,080 1.8-27.1 4.2-78.2 2.6-71.8 No 17.2
     ^Japan 264-2,509 2.2-3.4 10.0-15.0 6.9-10.2 *National 31.5
     Republic of Korea 20,234 6.2 16.7 12.5 No 76.2
     Singapore 1,013 4.6 11.6 8.9 Private sector 47.9
     Philippines 1,991-2,008 8.9-9.2 12.1-13.4 16.6-17.0 National 7.7
(Manila and Rizal) 
     Malaysia (Penang) 342 8.4 12.2 12.5 National 22.2
South-East Asia
     ^Thailand 459-3,214 11.1-18.0 14.0-32.0 11.8-26.1 Pilot 60.2
     ^India 87-4280 8.8-36.4 6.5-24.1 8.9-24.5 Pilot 4.9
Table 2. Cervical Cancer (CC) Incidence Rate in Asia from 2003-2007 Based on Available Population-Based Cancer 
Registries from International Agency for Research on Cancer, and Cervical Cancer Prevention Programmes
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post-licensure surveillance for HPV vaccines support 
an excellent safety profile (Macartney et al., 2013). Like 
other vaccines, adverse reactions (i.e. fatigue, redness, 
swelling, pain) have been reported from HPV vaccine 
trials/population studies, but most were mild or moderate 
in intensity, are self-resolving, and only occur in a small 
proportion of individuals (Garland, 2016). Although more 
serious adverse reactions such as syncope, anaphylaxis, 
Guillain-Barré syndrome and venous thromboembolism 
have occurred following HPV vaccination, there is no 
evidence that these events occur at higher rates compared 
with those in unvaccinated individuals, and in some 
cases, patients who had anaphylaxis or syncope following 
HPV vaccination no longer had the reactions when they 
were re-vaccinated with HPV vaccine (Macartney et al., 
2013). In Japan, medical conditions such as complex 
regional pain syndrome (CRPS) and postural orthostatic 
tachycardia syndrome (POTS) post vaccination have led 
to the suspension of the HPV vaccination programme, 
following lobbying by the affected families and like-
minded health professionals. This is despite a review 
by the WHO’s Global Advisory Committee on Vaccine 
Safety (GACVS) which concluded there was no evidence 
to suggest a causal association between the HPV vaccine 
and the adverse events (GACVS, 2015). Moreover, the 
International Papillomavirus Society (IPVS) supports 
the safety of  these prophylactic vaccines (Garland 
et al., 2016). Mongolia, which has one of the highest 
cervical cancer rates in Asia (age-standardised rate of 
24.3/100,000) (Globocan, 2012) has also been affected 
by allegations that HPV vaccines are unsafe and lead to 
infertility. This resulted in the cessation of a pilot HPV 
vaccine introduction organised by the Ministry of Health 
in Mongolia and the Millennium Challenge Corporation, 
USA to vaccinate 14,063 school girls aged 11-15 years 
old with 4vHPV after only 9,111 girls were vaccinated.
There are also social and cultural factors that affect the 
uptake of HPV vaccination. The lack of knowledge and 
awareness of HPV associated diseases has led to refusal to 
take up the vaccine in Peru and countries in Sub-Saharan 
Africa (LaMontagne et al., 2011; Perlman et al., 2014). 
The fact that HPV is a sexually transmitted infection 
has led some parents to feel uncomfortable vaccinating 
their child because of religious and cultural beliefs, or 
simply because they fear that it will encourage the girl 
to become promiscuous (Joseph et al., 2012). This has 
also led to inconsistent HPV vaccine recommendations 
by some health professionals, who feel that they are 
promoting pre-marital sex (Krupp et al., 2010). Research 
has shown that there was no increase in sexual activity 
in girls who had received HPV vaccine compared with 
girls who did not in the USA (Liddon et al., 2012). 
These misconceptions highlight the need to create and 
improve awareness about HPV, including the prevention 
and treatment methods, both within the communities, 
and among health care professionals. A cross-sectional 
study in India, Peru, Uganda and Vietnam, and a study in 
Cambodia have demonstrated that increased awareness 
and knowledge has led to increased rates of HPV vaccine 
uptake (LaMontagne et al., 2011; Wadhera et al., 2015). 
the world (age-standardised rate of 37.5/100,000) (Law 
et al., 2013), and this may also be true for other LMICs 
in Asia, but detailed studies are lacking. 
Human papillomavirus infection is the most common 
sexually transmitted infection and there is an increased 
risk of acquiring the infection with multiple sexual 
partners. Therefore, it is important to recognise that certain 
populations [i.e. female sex workers (FSWs) and men who 
have sex with men (MSM); termed high-risks groups] are 
at substantially higher risk of acquiring the infection, and 
therefore risk of HPV-associated cancers. At the same 
time, they are also likely to be responsible for transmitting 
HPV in the community. Information regarding the burden 
of HPV-associated diseases in these populations would 
be beneficial for governing bodies to make informed 
evidence-based decisions about HPV vaccination policy, 
which might include vaccination of boys in addition to 
girls, as well as having vaccination campaigns for these 
high-risk groups. These high-risks groups are common in 
LMICs in Asia (Caceres et al., 2006; Pruss-Ustun et al., 
2013), so the need for HPV vaccines is greater, and it may 
be necessary to consider specific strategies for them. The 
risk of anal cancer for MSM, usually due to HPV type 
16, is very high and is greater among men with human 
immunodeficiency virus ( Silverberg et al., 2012). The risk 
of HPV-associated cancer for FSWs is unknown, but it is 
likely to be very high.  Although most individuals in these 
two high-risk groups have already been exposed to HPV, 
and may be actively infected with one or more types, the 
benefits arising from protection against types to which 
they are not currently infected may substantially reduce 
their cancer risk, especially since the higher valency 
9vHPV is now available.
Barriers to HPV vaccine introduction
Several barriers and challenges against the introduction 
of HPV vaccines exist in LMICs. The high cost of 
the HPV vaccines and logistical challenges are major 
issues hindering the HPV vaccine introduction. These 
can be alleviated with the help of preferential pricing 
mechanisms and philanthropic organisations (although 
sustainable financing is needed in the long term), as 
well as the use of reduced-dose schedules for girls under 
15 years old as recommended by the World Health 
Organization (WHO). For example, Gavi the Vaccine 
Alliance (formerly known as the Global Alliance 
of Vaccines and Immunization) has supported HPV 
immunization programs in Rwanda, Uzbekistan and 
Bhutan. In the case for Fiji, a middle-income country, 
the recent national HPV vaccine introduction in 2013 
was achieved with the assistance of Australian Aid, the 
Department of Foreign Affairs and Trade. Countries that 
have initiated demonstration projects or pilot programs 
include Vietnam, Mongolia, and Lao People’s Democratic 
Republic (PDR) with financial assistance from PATH, 
Gavi and the Millennium Challenge Corporation Fund.
Another significant barrier to HPV vaccine introduction 
is the perception that the HPV vaccine is not safe. To 
date, more than 200 million doses of HPV vaccines have 
been administered globally, and a review of pre- and 
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In addition, this approach (community education and 
increasing awareness of HPV vaccine) has also led to 
broad acceptance and uptake of the HPV vaccine in the 
HPV vaccine introduction campaign in Fiji (La Vincente 
et al., 2015).
Cost-effectiveness of HPV vaccination
The cost-effectiveness of HPV vaccination in a 
population depends largely on vaccine prices and 
are important to inform vaccination policy in a given 
country (Fesenfeld et al., 2013). Several studies on 
cost-effectiveness of HPV vaccination have been 
undertaken in countries of Asia. Not surprisingly, they 
have found HPV vaccination is most cost-effective if the 
vaccine is procured at a Gavi-negotiated price for LMICs, 
and also in settings where there is weak or no screening 
programmes (Fesenfeld et al., 2013). However, different 
assumptions (i.e. vaccine price, coverage, herd protection 
and outcomes) were considered for the different studies 
based on a three-dose schedule, which makes direct 
comparison of the results difficult. Furthermore, the new 
recommendation by WHO of a two-dose HPV schedule 
will increased cost-effectiveness for countries in Asia.
HPV vaccine program implementation
It is widely recognised that in order to effectively 
protect populations from HPV-related diseases, the 
HPV vaccine should be given as part of a country’s 
national immunization schedule to young school girls 
(aged 9-13 years), before sexual debut, as HPV vaccine 
efficacy against HPV infection is the highest when given 
to individuals who have not had prior HPV infection 
(Future I/II Study Group et al., 2010; Lehtinen et al., 
2012). School-based immunization campaigns increase 
the likelihood of reliable follow-up for administration of 
subsequent dose(s), and have been demonstrated to have 
high completion rate in not just high-income countries 
(i.e. Australia and Canada), but also in LMICs (i.e. 
Malaysia) (Brotherton et al., 2013; Malaysia Ministry of 
Health, 2013; McClure et al., 2015). The school-based 
immunization approach also been demonstrated in 
pilot HPV vaccine programs in Vietnam and Bhutan 
(LaMontagne et al., 2011; Dorji et al., 2015). However, 
it is important to note that school attendance may be 
much lower in LMICs, especially children living in 
rural settings, and so community outreach activities are 
important to achieve high vaccine awareness and uptake. 
Alternatively, primary school attendances are generally 
higher, so countries may elect to use the final year of 
primary school as the target group for vaccination, to 
minimize the need to capture out-of-school children, and 
thereby maximizing coverage.
However, an important point to note is that while 
HPV vaccines are extremely effective, they do not protect 
against all oncogenic HPV types. This justifies the need 
for continued robust cervical cancer prevention programs 
that encompass HPV vaccination, cervical cancer 
screening, education and other healthcare programs. 
Several cervical cancer screening methods for LMICs 
have also been developed (Denny et al., 2006). In addition, 
a new program (HPV-FASTER) has also been proposed to 
expand HPV vaccination to women aged up to 45 years to 
minimise the number of lifetime screening visits, although 
more studies are needed to address the various research 
gaps (e.g. exact age limit for vaccination, and screening) 
(Bosch et al., 2016). 
In conclusion, a significant burden of HPV-related 
disease occurs in LMICs in Asia, where HPV vaccination 
is not available or is not part of the national schedule. In 
addition, effective management of HPV diseases requires 
a multifaceted approach including HPV vaccination, 
a cervical cancer screening program with effective 
monitoring and strong referral systems. With Gavi support 
and the WHO revision of the number of recommended 
HPV doses (three to two doses), LMICs are now in 
a better position than five years ago to introduce this 
vaccine. Philanthropic organisations have supported pilot 
HPV vaccine programs in countries such as India, Laos 
PDR, Vietnam, Peru, Mongolia and Uganda, which may 
lead to a national immunization program. More LMICs, 
particularly those in Asia need to have improved access 
to crucial life-saving HPV vaccination programs. To date, 
only Malaysia and Bhutan have successfully introduced 
HPV vaccine into their national immunization schedule 
with high coverage (school-based program; Malaysia: 
current schedule of two doses of 4vHPV to all school 
girls aged 13 year-old girls; Bhutan: three-dose 4vHPV 
schedule to 12 year-old girls). The lessons learnt from 
establishing the Malaysia and Bhutan national HPV 
immunization programs are valuable for LMICs in Asia.
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